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Abstract 
Background: Protein kinases have been shown to be key drug targets, especially in the area of oncology. It is of 
interest to explore the possibilities of protein kinases as a potential target class in Plasmodium spp., the causative 
agents of malaria. However, protein kinase biology in malaria is still being investigated. Therefore, rather than assay-
ing against individual protein kinases, a library of 4731 compounds with protein kinase inhibitor-like scaffolds was 
screened against the causative parasite, Plasmodium falciparum. This approach is more holistic and considers the 
whole kinome, making it possible to identify compounds that inhibit more than one P. falciparum protein kinase, or 
indeed other malaria targets.
Results: As a result of this screen, 9 active compound series were identified; further validation was carried out on 4 
of these series, with 3 being progressed into hits to lead chemistry. The detailed evaluation of one of these series is 
described.
Discussion: This screening approach proved to be an effective way to identify series for further optimisation against 
malaria. Compound optimisation was carried out in the absence of knowledge of the molecular target. Some of the 
series had to be halted for various reasons. Mode of action studies to find the molecular target may be useful when 
problems prevent further chemical optimisation.
Conclusions: Progressible series were identified through phenotypic screening of a relatively small focused kinase 
scaffold chemical library.
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Background
Resistance of Plasmodium falciparum to existing therapy 
is emerging rapidly [1, 2] and, therefore, much effort is 
being devoted to discover, develop and deliver new treat-
ments for malaria. The Drug Discovery Unit (DDU) at 
the University of Dundee has assembled a number of 
Focused Compound Libraries tailored to certain target 
classes, such as kinase, protease and phosphatase inhibi-
tors. Protein kinases have been suggested as targets for 
drug discovery in Plasmodium species [3, 4]. The malaria 
kinome is predicted to contain 85–99 protein kinases [5, 
6], of which 65 belong to the eukaryotic protein kinase 
family and 20 belonging to the FIKK family, unique to the 
Apicomplexa [6, 7]. The malaria kinome also differs from 
the human kinome in that it does not contain tyrosine 
kinases [6]. Malaria kinases typically show only 35–60% 
sequence identity to their mammalian orthologues sug-
gesting that selective inhibition is possible [8]. Indeed, 
success has been reported with inhibitors of phosphati-
dylinositol-4-OH kinase (PI(4)K) [9, 10], albeit this 
enzyme is a lipid kinase. Although 36 of the 65 eukaryotic 
protein kinases in P. falciparum have been genetically 
validated as drug targets [11], no inhibitors of these have 
been developed into clinical candidates to date. However, 
protein kinase biology in P. falciparum is still being inves-
tigated. Therefore, rather than assaying against individ-
ual protein kinases, it was decided to screen a library of 
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compounds with protein kinase scaffolds in a whole cell 
assay (phenotypic screening).
Phenotypically screening potential protein kinase 
inhibitors has the advantage of screening the whole 
kinome in a more integrated way, and also gives the 
opportunity to consider a polypharmacology approach 
by identifying compounds that inhibit more than one P. 
falciparum protein kinase or, indeed, other targets. As 
part of a pilot study with Medicines for Malaria Ven-
ture (MMV), the DDU Kinase Inhibitor library [12], and 
the commercially available Prestwick Library [13], were 
screened phenotypically against P. falciparum using a 
DDU optimized SYBR Green assay platform [14]. As a 
result of further validation, characterization and expan-
sion around key hits, this programme has yielded 9 con-
firmed scaffolds of interest with sub-micromolar potency.
At the time of the screen, there was no significant pub-
lished work on 5 of the 9 series, although 2 of the series 
were part of the ongoing MMV portfolio. Further work 
was carried out to validate 4 of the series, 3 of which 
demonstrated sub-micromolar potency against P. falci-
parum with initial SAR and reasonable selectivity against 
the mammalian MRC5 cell line. The MRC5 cell line is a 
normal diploid human fibroblast cell line, which is com-
monly used as a typical counter-screen [15]. These series 
were chemically tractable, demonstrated excellent selec-
tivity over a panel of mammalian kinases and thus offered 




Cultures of 3D7, a P. falciparum chloriquine sensitive 
reference strain, were maintained in a 5% suspension of 
A+ human red blood cells (obtained from East of Scot-
land Blood Transfusion Service, Ninewells Hospital, 
Dundee, UK) cultured in RPMI 1640 medium (pH 7.3) 
supplemented with 0.5% Albumax II (Gibco Life Tech-
nologies, San Diego, CA, USA), 12  mM sodium bicar-
bonate, 0.2 mM hypoxanthine, and 20 mg/l gentamicin 
at 37 °C, in a humidified atmosphere of 1%  O2, 3%  CO2 
with a balance of nitrogen. Growth inhibition was quan-
tified using a fluorescence assay utilizing the binding of 
SYBR Green I to double stranded DNA, which emits a 
fluorescent signal at 528 nm after excitation at 485 nm. 
The SYBR Green assay system was adapted to maximize 
robustness and to align with available automation sys-
tems. The Prestwick Library then used as a pilot screen 
to validate the performance of the optimized assay. 
Mefloquine (potency range 30–60  nM) [16] was used 
as a drug control to monitor the quality of the assay 
(Z’ =  0.6–0.8, Signal to background ≥  3, where Z’ is a 
measure of the discrimination between the positive and 
negative controls on a screening plate). Single point 
screens were carried out, and the potency of com-
pounds of interest was determined in duplicate on two 
independent occasions. A 96-well  [3H]-Hypoxanthine 
incorporation assay [17] was also developed as a sec-
ondary assay in order to validate key compounds from 
each hit series in an orthogonal platform. Compound 
bioactivity from both assays was expressed as  EC50, the 
effective concentration of compound causing 50% para-
site death.
Mammalian toxicity screening
A counter-screen against normal diploid human fibro-
blasts (MRC-5 pd30, ECACC 84101801) was carried 
out to exclude non-selective, and toxic compounds as 
previously published [18]. Cells were plated and incu-
bated overnight to allow them to adhere as monolayers. 
A working stock of each test compound was transferred 
to an intermediate 384-well plate and pre-diluted with 
minimum essential media (MEM). The pre-diluted stocks 
were then transferred onto the cell monolayers, and the 
plates were incubated for 68 h. Resazurin, to a final con-
centration of 50 μM was added to each well, after which 
plates were incubated for a further 3 h and measured for 
fluorescence (λex = 528 nm, λem = 590 nm). A standard 
reference compound, doxorubicin, was included on all 
counterscreen plates to monitor the quality of the assay 
(potency range 200–400 nM).
In vitro cell assay data analysis
All data were processed using IDBS ActivityBase [19]. 
Raw data were converted into per cent inhibition through 
linear regression by setting the high inhibition control as 
100% and the no inhibition control as 0%. Quality con-
trol criteria for passing plates were as follows: Z’  >  0.5, 
S:B > 3, %CV(no inhibition control) < 15. The formula used to 
calculate Z’ is 1− 3×(StDev_high+StDev_low)
ABS(Mean_high−Mean_low)
.
All  EC50 Curve fitting was undertaken using XLFit ver-
sion 4.2 using Model 205 with the following 4 paramet-
ric equation: y = A+ B−A
1+(C/x)
D
, where A = % inhibition 
at bottom, B = % inhibition at top, C = EC50, D = slope, 
x =  inhibitor concentration and y = % inhibition. If the 
curve did not reach 100% of inhibition, B was fixed to 100 
when at least 50% of inhibition was reached.
Compound library
Protein kinases have been suggested as potential drug 
targets in malaria [3, 7]. However, rather than screen 
each individual kinase, a more rapid approach would 
be to screen the malaria parasite phenotypically. This 
has a number of advantages: it is not necessary to clone 
and overexpress each kinase and develop an individual 
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assay; the protein kinase is in its relevant state of activa-
tion with the relevant substrates present; this only selects 
cell penetrant compounds and compounds that have a 
lethal effect; it would detect compounds that were acting 
on multiple proteins. The disadvantages of this approach 
include the unknown identity of the target(s), which 
could make optimization of hits problematic, particularly 
if there were pharmacokinetic or toxicological issues.
The Dundee library of protein kinase scaffolds was 
assembled as described in Brenk et  al. [12]. The aim of 
this library was to find chemical start points for drug dis-
covery programmes, so the molecules were deliberately 
kept low molecular weight, giving room for optimisation. 
In brief, a review of the literature and patents was carried 
out by industry experienced chemists to identify scaffolds 
that bind in the adenine pocket of all protein kinases, to 
the so-called hinge region. Allosteric inhibitors were not 
considered. The hinge region is part of the backbone that 
forms a hydrogen bonding network with the adenine 
moiety of ATP. Decoration of these scaffolds can achieve 
varying degrees of selectivity for particular kinases. These 
scaffolds were then searched for using an in silico data-
base of 2.6 million discrete compounds compiled from 
the catalogues of 26 suppliers. The initial selections were 
further screened to eliminate non-lead like compounds, 
using over 100 filters based on chemically reactive groups 
and toxicophores. This process identified in excess of 
150 scaffolds with at least one commercially available 
example. To limit the total number of compounds in the 
screening collection, a limit of the most diverse 50 exam-
ples of each scaffold was set using Tanimoto Indices to 
assess similarities. At the time of the screen this library 
contained 4731 individual compounds.
Hit discovery
The 4731 compounds from the DDU curated kinase 
library were screened against P. falciparum at a single 
concentration of 3 μM using a fluorescence-based assay. 
Compounds with a percentage inhibition (PI) > 30 were 
retested in duplicate and 120 hits were progressed to 
potency determination against both P. falciparum and 
human MRC5 cells to assess toxicity. Potency values 
were established using a 10-point, half-log serial dilution 
of each compound from a top concentration of 15 µM. 
Two independent assays were run. Screening data sta-
tistics were comparable with those obtained in the pilot 
screen.
To further establish all discovered hits, structural iden-
tity and purity of all compounds progressed to potency 
was confirmed by LC/MS. Fresh material was sourced by 
resupply or resynthesis to confirm activity in the original 
assay and in an orthogonal (hypoxanthine incorporation) 
assay.
Kinase profiling
The compounds were cherry picked from library mate-
rial and tested at 10  µM. This was carried out at the 
International Centre for Kinase Profiling, University of 
Dundee [20], where the principal assay method utilized 
is a radioactive filter-binding assay using 33P ATP. At the 
time of screening, there were 76 protein kinases in the 
panel. Whilst this represents a relatively small proportion 
(~  15%) of the mammalian kinome (518 predicted pro-
tein kinases in humans [21]), it should give an indication 
as to whether the compound is selective or promiscuous. 
The profiled compounds were checked for purity and 
molecular identity by LCMS.
LCMS QA
LCMS analysis of the 120 compounds progressed into 
 EC50 determination was conducted on an Agilent tech-
nologies 1200 series LC/Agilent technologies 6130 
quadrapole LC/MS, eluting with 20–90% MeCN in 0.1% 
aqueous formic acid. 96 of the 120 compounds had > 85% 
purity by diode array and confirmation of the expected 
mass to give an 80% pass rate.
Results
Pilot screen
In order to validate the optimized assay, the commer-
cially available Prestwick Library (1120 compounds) 
was screened in duplicate at single concentration. A 
number of compounds with known anti-malarial prop-
erties were identified from this pilot screen, and results 
compare favourably with published data [22] (Fig.  1, 
Table 1 and Additional file 1: Table S1 for full list of the 
hits), thus indicating that the DDU optimized assay was 
fit for purpose. The final assay was demonstrated to be 
robust (Z’ = 0.84 ± 0.01), and reproducible (mefloquine) 
 EC50 = 48 ± 4 nM (n = 24).
Primary screen
The frequency distribution plot of percentage inhibi-
tion for the primary screen of the focused kinase library 
against P. falciparum is shown in Fig.  2a, illustrating a 
classical normal distribution. A cut-off of 30% inhibition 
was chosen to define an initial hit (3 standard deviations 
away from the averaged high controls). Table 2 summa-
rizes the numerical results from the primary screen.
The 210 putative hits identified from the kinase set 
primary screen were cherry picked and retested in a 
duplicate single point screen (3 μM). Figure 3 shows the 
excellent correlation between the two replicate retest 
data points. For those compounds returning  >  50% 
inhibition in the primary assay the confirmation rate to 
retest was 68%. 120 compounds with a percentage inhi-
bition of > 80% were selected for progression to potency 
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testing. Ten-point dose response curves were generated 
and assayed in both P. falciparum and mammalian MRC5 
(human lung fibroblasts) proliferation assays. A range of 
potencies (Table 3) were identified against P. falciparum, 
with the majority of compounds being inactive in the 
MRC5 counter-screen with an  EC50 > 15 μM.
Hit validation
Series classification
Hit compounds that had  EC50 values of less than 1  μM 
were grouped into compound series using in silico core 
fragment identification. The sub-micromolar hits iden-
tified from screening the DDU focused kinase library 
were grouped into 9 compound series (summarized in 
Table  4). The core structures common to hits in each 
compound series are highlighted in red and the most 
active example identified in the screen exemplified with 
the substituents illustrated in black. Most of the com-
pound series were apparent singletons with a large drop 
in activity to the second most active member of the com-
pound series.
In order to avoid overlapping the work conducted in 
this programme with other MMV collaborations, the 
series we subsequently focused upon in hit expansion 
were MMV02 [23], MMV03 and MMV04 [24, 25], as pre-
viously published.
Orthogonal testing with  [3H]‑hypoxanthine incorporation 
assay
The traditionally used  [3H]-hypoxanthine incorporation 
assay is labour intensive, low throughput and requires 
the use of radio-labelled hypoxanthine. Therefore, it was 
used only to test and confirm key series representative 
hits that had been identified in the SYBR Green assay. 
The assay as developed yielded acceptable performance 
metrics (Z’  =  0.68  ±  0.05 and S/B  >  300). In addition, 
mefloquine returned  EC50 values of 7–10  nM in this 
assay, which were consistent with those reported by the 
SYBR Green screening platform. Table  5 demonstrates 
that all 9 MMV series were validated in this orthogonal 
platform and that the hits all returned potency values 
within acceptable ranges of the SYBR Green assay (ratios 
between 1 and 4 observed).
Kinase profiling
Ten compounds across the 9 MMV series were screened 
in vitro against a panel of 76 mammalian kinases by the 
Division of Signal Transduction Therapy (DSTT) at The 
University of Dundee for selectivity assessment.
Fig. 1 Prestwick library screen (concentration approximately 5 μM). a Correlation plot of the percentage of inhibition of the two replicate values. b 
Frequency distribution plot expressed in terms of standard deviation units (s) from the median value of the controls. In blue are highlighted the 58 
putative hits with percentage of inhibition higher than 3 s units
Table 1 Percentage inhibition of  the growth of Plasmo-
dium falciparum of  known anti-malarials in  the Prestwick 
Library




Chloroquine diphosphate 0.004 104 ± 1
Pyrimethamine 0.008 101 ± 2
Artemisinin 0.007 100
Primaquine diphosphate 0.004 100 ± 4
Hydroquinine hydrobromide 
hydrate
0.005 99 ± 2
Atovaquone 0.005 99 ± 2
Mefloquine hydrochloride 0.005 97.4 ± 0.4
Proguanil hydrochloride 0.007 49 ± 4
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The selected compounds, demonstrated excellent selec-
tivity with respect to the 76 kinases tested (Additional 
file 1: Table S2). The lack of cross-activity against mam-
malian kinases means that either the identified series are 
selectively inhibiting plasmodium protein kinase(s) or 
they have a different, non-kinase based, mode of action. 
Future assessment of these series against a Plasmodium 
kinase panel will help clarify the mode of action.
Medicinal chemistry evaluation
Further discussion on the preliminary structure activity 
relationships is included in Additional file 1
The series not already under development by MMV at 
the time of screening were MMV02, MMV03, MMV04 
and MMV10. As such, efforts focused on establishing 
some early structure activity relationships for the 4 unex-
plored series.
MMV02 consists of a 1,3,5-tri-substituted pyrimidine 
core (Fig.  4). The work on this has recently been pub-
lished [23]. The active MMV02 hit A002 possessed a 
4-aminopyridine substituent as the  R2 group which was 
unique within the compound set screened; it was hypoth-
esized that the pyridine nitrogen may be forming a criti-
cal hydrogen bond with the molecular target. A further 
23 examples of this scaffold were purchased and an addi-
tional seven examples tested using stocks of compounds 
in the DDU general compound set. Interestingly the 
five most active examples all contained a 4-aminopyri-
dyl group at the  R2 position (for instance A0021). How-
ever, A0022 was only tenfold less active than A0002. 
A0022 possesses a 4-trifluoromethoxyaniline instead of 
the 4-aminopyridine of compound A0002 (Table 6). The 
ether oxygen of 4-trifluoromethoxyaniline group is a very 
Fig. 2 Kinase Set Screen. a Distribution of percentage of inhibition. In blue are highlighted the hits with percentage of inhibition higher than 30%. 
b Correlation plot between retest replicates. Reconfirmed hits are highlighted in the blue circle
Table 2 Summary of primary screen
Number of compounds screened 4371
Hit identification cut-off (3 × SD from mean of 0% inhib. controls) 30%
Number of putative hits cherry picked 210
Fig. 3 EC50 Correlation of potency replicates in Plasmodium falcipa-
rum
Table 3 Kinase set potency ranges
EC50 (μM) Number of compounds
EC50 < 1 21
1 < EC50 ≤ 3 51
3 < EC50 ≤ 10 43
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Compound A0002 A0003 A0004
EC50 P. falciparum (μM) 0.2 0.6 0.7
EC50 MRC5 cells (μM) 6 > 15 > 15
cLogP 4 3.2 2.9
cLogD 4 3.2 2.9
TPSA (Å2) 51 60 68
MW 342 346 405
Heavy Atoms 26 25 26
No. of examples < 1 μM 1 1 2
Validated hit series Yes Yes Yes
Series ID
MMV05 MMV06 MMV08
Compound A0005 A0006 A0008
EC50 P. falciparum (μM) 0.01 0.04 0.6
EC50 MRC5 cells (μM) 1 > 15 0.02
cLogP 5.4 4.2 5.7
cLogD 5.4 4.2 5.7
TPSA (Å2) 71 57 70
MW 407 355 382
Heavy Atoms 31 27 27
No. of examples < 1μM 1 1 1
Validated hit series No No No
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poor hydrogen bonding unit, which is unlikely to be able 
to form a hydrogen bond to the hinge NH of a kinase [26, 
27]. This suggests that kinase inhibition is unlikely to be 
responsible for the mode of action for this series.
MMV04 is a 2,6-disubstituted quinoline-4-carboxamide 
(Fig.  5). Work describing this series has been published 




Compound A0009 A0010 A0011
EC50 P. falciparum (μM) 0.2 0.6 0.6
EC50 MRC5 cells (μM) > 15 > 15 6
cLogP 2.6 2.4 4.3
cLogD 2.6 2.4 3.9
TPSA (Å2) 55 67 58
MW 348 348 482
Heavy Atoms 24 23 35
No. of examples < 1μM 1 1 1
Validated hit series No No No
Table 5 Comparison of  compound  EC50 values obtained by  fluorescent (SYBR Green), and  radiometric 
 ([3H]-hypoxanthine) assay platforms





MMV02 A0002 0.23 ± 0.04 0.06 ± 0.07 4
MMV03 A0003 0.59 ± 0.12 0.15 ± 0.25 4
MMV04 A0004 0.70 ± 0.07 0.41 ± 0.47 2
MMV05 A0005 0.01 ± 0.00 0.01 ± 0.00 1
MMV06 A0006 0.04 ± 0.01 0.04 ± 0.01 1
MMV08 A0008 0.56 ± 0.09 0.30 ± 0.10 2
MMV09 A0009 0.23 ± 0.09 0.15 ± 0.09 2
MMV10 A0010 0.55 ± 0.08 0.35 ± 0.13 2




Fig. 4 The MMV 02 Scaffold
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A0004 and A0031. In the hit expansion programme, 84 
analogues were purchased. Modifying the  R1 group had 
a significant effect on activity with 4-tolyl A0031 fivefold 
more active than A0004, (Table 7). The 3-pyridyl amide in 
A0004  (R2 position) could be replaced with ethyl phenyl-
4-carboxylate A0024 with no significant effect on activity. 
The  R2 region tolerated large changes to ring electronics 
and steric bulk (A00410), suggesting that this region is 
not critical for maintenance of activity. Examples A0004 
and A00421 demonstrated that the bromine  (R3) can be 
replaced with the smaller chlorine group with no loss of 
activity and a reduction in the MW of 55.
MMV10 was identified as a singleton from the 
screen. The series was defined as a 3,5,7-trisubstituted 
3-hydroxy-indolin-2-one (Fig.  6). The hit compound 
A0010 possesses a 2-methylimidazo[1,2-a]pyridin-3-yl 
which could be responsible for a critical hydrogen bond, 
Table 4. The initial hit was no longer commercially avail-
able. An additional 15 examples were purchased, none of 
which were progressed into  EC50 determination. MMV10 
could not be validated as a hit series nor has the origi-
nal hit been reconfirmed. In order for MMV10 to be 
progressed further, the original hit would need to be re-
synthesized along with some close analogues.
Following hit validation, the hit to lead and lead opti-
misation medicinal chemistry programmes for series 
MMV02 and MMV04 have been published elsewhere 
[23–25].
MMV03 validation and hit expansion
MMV03 has a 1,3-disubstituted pyrazole-4-carboxamide 
core (Fig. 7). Only one sub-micromolar hit, A0003, was 
identified following screening, Table 8. A further 62 ana-
logues were sourced and tested single point at 10  μM; 
of these, 11 compounds active in single point were pro-
gressed into  EC50 determination returning  EC50 values 
ranging from 0.32 to 7.2 µM. A0003 remained the most 
active example in this series. All examples with  EC50 val-
ues less than 10 µM have a pyridine-like (H-bond accep-
tor) nitrogen containing group on the amide, though the 
nitrogen can be orientated in the 2, 3 or 4 position for 
instance compounds A0003, A0032, and A0033.
The most active compound of the original hit series 
displayed moderate activity in  vitro and good selectiv-
ity index (>  100-fold) against human MRC-5 cell line 
(Table  8). However, the ligand-lipophilicity efficiency 
(LLE or LiPE) [28] was low and the calculated property 
forecast index (cPFI) [29], an indicator of compound 
development potential, was unfavourably high. The aim 
of the initial hit optimization programme was to improve 
both the physicochemical properties and potency of this 
series (with an aim of Pf  EC50 (3D7) < 0.1 μM).
Initial modifications were directed towards improving 
the physicochemical properties of the compounds, par-
ticularly reducing lipophilicity and the number of aro-
matic rings and therefore reducing cPFI. Large numbers 
of aromatic rings are associated with poor compound 
development potential [30, 31]. The substituents  R1,  R2 
Table 6 Key MMV02 SAR





















Fig. 5 MMV04 Scaffold
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and  R3 (see Fig.  7 and Table  8 for definitions of the R 
groups) were aromatic rings in the initial hit.
First, the amide substituent  (R3) was extensively 
explored. All compounds with activity below 1 μM have 
either a pyridine or a 2-benzoimidazole moiety at the 
 R3 position. Five membered ring heterocycles, basic and 
alkyl substituents, with improved cPFI, at the  R3 position 
led to a drop in potency. The  R2 substituent could toler-
ate thiophene, pyridine and phenyl rings but compounds 
with an alkyl substituent, methyl or isopropyl, showed a 
significantly drop in activity  (EC50 > 10 μM). Finally, the 
aromatic ring at  R1 tolerated an electron withdrawing 
(CN) and donating (F) groups. However, replacement 
of the aromatic ring with an alkyl group (tert-butyl and 
methyl) was not tolerated.
Therefore, none of 3 aromatic substituents on 
MMV03  scaffold could be replaced by an alkyl group 
making the optimization of physicochemical properties 
problematic. Additionally, the potency and LLE of the hit 
has not been improved. As a result work on this series 
was discontinued.
Conclusion
A P. falciparum SYBR Green assay platform has been 
adapted to robotics available in the University of Dundee 
DDU, demonstrating robust, reproducible output with 
performance and results to match the traditionally used 
 [3H]-hypoxanthine incorporation assay. Phenotypic 
screening of an in-house protein kinase inhibitor library 
identified 9 chemical scaffolds. All series were confirmed 
using a combination of LCMS QA of the DMSO library 
stocks and hit repurchasing where possible. Furthermore, 
Table 7 MMV04 SAR





































Fig. 7 MMV03 Scaffold
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4 of the 9 compound series (MMV10, MMV02, MMV03, 
MMV04) were further validated as hit series through hit 
expansion with commercially available compounds. Of 
these validated series, 3 compound series showed some 
early SAR, were chemically tractable, and had not pre-
viously been developed as potential anti-malarial drugs. 
These start points were suitable for progression into hit 
to lead programs for novel anti-malarial therapy.
Whilst the screening library was based on scaffolds 
designed to bind to the hinge region of eukaryotic 
protein kinases, there is no evidence that the com-
pounds actually function in this manner. Indeed, the 
only series for which information is available is the 
MMV04 series, where the preclinical candidate tar-
gets eukaryotic elongation factor 2 (eEF2) involved in 
protein synthesis [24]. Further work will be required 
to elucidate the mode of action of the other hit series 
using approaches such as protein kinase profiling, whole 
genome sequencing of resistant mutants or chemical 
proteomics.
Table 8 MMV03 SAR
Compound R1 R2 R3 cLogP cPFI P. fal.  EC50 (µM) LLE MRC5 EC50 (µM)
A0003 (Hit) 3.2 7.2 0.3 3.2 >50
A0032 3.4 8.4 0.5 2.9 21
A0033 3.2 7.2 0.7 2.9 39
A0034 4 9.1 0.8 2 13
A0012 3.4 7.4 6 1.9 24
A0036 3.5 6.6 18 1.1 50
A0037 3.6 5.1 13 2.7 18
A0038 2.3 6.3 2 3.2 18
A0039 i -Pr 2.6 5.6 21 2.1 50
A0040 Me 2.1 5.1 10 2.8 50
A0041 3.2 8.2 0.4 3.2 15
A0042 3.4 8.4 0.6 2.8 14
A0043 t Bu 3.7 7.7 14 1.2 >50
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